Published in Support Care Cancer on September 30, 2010
Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain. Patient Prefer Adherence (2012) 0.84
Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study. Oncologist (2016) 0.75
Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer (2001) 3.40
The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain (2008) 2.48
A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain (2006) 1.38
Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer (1996) 1.33
Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol (2004) 1.32
Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer (1998) 1.29
Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol (2007) 1.18
Switching from methadone to a different opioid: what is the equianalgesic dose ratio? J Palliat Med (2008) 1.12
Opioid switching: a systematic and critical review. Cancer Treat Rev (2006) 1.10
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain (2008) 1.04
Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage (2009) 1.00
Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. Pain (2002) 0.97
Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer (2007) 0.94
A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med (2007) 0.93
Opioid poorly-responsive cancer pain. Part 2: basic mechanisms that could shift dose response for analgesia. J Pain Symptom Manage (2001) 0.91
Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage (2004) 0.90
The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen. Clin J Pain (2010) 0.84
Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage (2004) 0.82
Profound morphine tolerance following high-dose methadone therapy. J Pain Palliat Care Pharmacother (2004) 0.77
Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study. J Palliat Med (2007) 0.76
Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study. J Pain Symptom Manage (2008) 0.75
Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol (2004) 1.95
High doses of oxycodone-naloxone combination may provide poor analgesia. Support Care Cancer (2011) 1.65
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain (2008) 1.04
Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage (2009) 1.00
Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage (2004) 0.99
Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer (2004) 0.98
Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage (2004) 0.97
Peritoneal catheter for continuous drainage of ascites in advanced cancer patients. Support Care Cancer (2008) 0.97
Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage (2005) 0.96
High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients. J Pain Symptom Manage (2008) 0.96
The use of high doses of oxycodone in an acute palliative care unit. Am J Hosp Palliat Care (2010) 0.96
A model of acute symptom control unit: Pain Relief and Palliative Care Unit of La Maddalena Cancer Center. Support Care Cancer (2002) 0.96
Opioid escalation in patients with cancer pain: the effect of age. J Pain Symptom Manage (2006) 0.95
Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain (2007) 0.93
Opioids and renal function. J Pain (2004) 0.93
Controlled sedation for refractory symptoms in dying patients. J Pain Symptom Manage (2008) 0.91
Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin (2012) 0.91
Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage (2003) 0.91
Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation. Oncology (2002) 0.90
Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage (2004) 0.90
Patients' and relatives' perceptions about intravenous and subcutaneous hydration. J Pain Symptom Manage (2005) 0.89
Long-term central venous catheterization via persistent left superior vena cava: a case report. Support Care Cancer (2003) 0.88
Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage (2006) 0.87
Opioid-induced or pain relief-reduced symptoms in advanced cancer patients? Eur J Pain (2006) 0.87
Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer (2002) 0.87
Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. Curr Med Res Opin (2010) 0.85
Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. J Palliat Med (2009) 0.85
Hyperalgesia and opioid switching. Am J Hosp Palliat Care (2005) 0.85
Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol (2005) 0.84
Celiac plexus block for pancreatic cancer pain: factors influencing pain, symptoms and quality of life. J Pain Symptom Manage (2003) 0.84
Pharmacological management of cancer pain in the elderly. Drugs Aging (2007) 0.84
The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen. Clin J Pain (2010) 0.84
Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. J Pain Symptom Manage (2011) 0.84
Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Clin Ther (2009) 0.83
Tools for identifying cancer pain of predominantly neuropathic origin and opioid responsiveness in cancer patients. J Pain (2009) 0.82
Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage (2006) 0.82
Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symptom Manage (2003) 0.81
Randomized double-blind, double-dummy crossover clinical trial of oral tramadol versus rectal tramadol administration in opioid-naive cancer patients with pain. Support Care Cancer (2005) 0.81
Pain syndromes in haematological malignancies: an overview. Hematol J (2004) 0.80
Outcome of opioid switching 4 weeks after discharge from a palliative care unit. Curr Med Res Opin (2011) 0.80
Local anesthetics for breakthrough pain in patients receiving intrathecal treatment for cancer pain management. Anesth Analg (2005) 0.80
Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support Care Cancer (2006) 0.80
When the progression of disease lowers opioid requirement in cancer patients. Clin J Pain (2010) 0.79
Opioids in pain management of blood-related malignancies. Ann Hematol (2006) 0.79
Does pain intensity predict a poor opioid response in cancer patients? Eur J Cancer (2011) 0.79
The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients. Clin J Pain (2013) 0.78
Itraconazole-fentanyl interaction in a cancer patient. J Pain Symptom Manage (2002) 0.77
Pain in malignant hematology. Expert Rev Hematol (2011) 0.77
Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. Tumori (2002) 0.77
Refractory death rattle: deep aspiration facilitates the effects of antisecretory agents. J Pain Symptom Manage (2010) 0.77
Opioid switching and burst ketamine to improve the opioid response in patients with movement-related pain due to bone metastases. Clin J Pain (2009) 0.76
Prevalence of opioid-related dysuria in patients with advanced cancer having pain. Am J Hosp Palliat Care (2010) 0.76
The use of opioids in the last week of life in an acute palliative care unit. Am J Hosp Palliat Care (2010) 0.75
Effectiveness and tolerability of amidotrizoate for the treatment of constipation resistant to laxatives in advanced cancer patients. J Pain Symptom Manage (2010) 0.75
Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study. J Pain Symptom Manage (2008) 0.75
Switching from oxycodone to methadone in advanced cancer patients. Support Care Cancer (2011) 0.75
Beginning again from the end. Palliat Med (2008) 0.75
Sympathetic blocks and disease progression modifying pain mechanisms. Reg Anesth Pain Med (2003) 0.75
Preliminary in vivo experimental evidence on intratumoral morphine uptake. Possible clinical implications in cancer pain and opioid responsiveness. J Pain Symptom Manage (2002) 0.75
Naloxone in treating central adverse effects during opioid titration for cancer pain. J Pain Symptom Manage (2003) 0.75
Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma. Breast Cancer Res Treat (2003) 0.75
Dialogues on complex analgesic strategies for difficult pain syndromes. Support Care Cancer (2004) 0.75
Block of interdigital nerves for cancer pain. J Pain Symptom Manage (2002) 0.75
Opioid plasma concentrations during a switch from transdermal fentanyl to methadone. J Palliat Med (2007) 0.75
Switching from methadone to tapentadol for cancer pain. J Pain Symptom Manage (2012) 0.75
Prolonged uncontrolled pain, psychological distress, and opioid escalation. J Pain Symptom Manage (2004) 0.75